200 related articles for article (PubMed ID: 35001204)
1. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.
Deng C; Zhao PY; Branham K; Schlegel D; Fahim AT; Jayasundera TK; Khan N; Besirli CG
Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1543-1550. PubMed ID: 35001204
[TBL] [Abstract][Full Text] [Related]
2. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
[TBL] [Abstract][Full Text] [Related]
3. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
[TBL] [Abstract][Full Text] [Related]
4. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec.
Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K
Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237
[TBL] [Abstract][Full Text] [Related]
5. The first gene therapy for
Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
[TBL] [Abstract][Full Text] [Related]
7. Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy.
Yang U; Gentleman S; Gai X; Gorin MB; Borchert MS; Lee TC; Villanueva A; Koenekoop R; Maguire AM; Bennett J; Redmond TM; Nagiel A
JAMA Ophthalmol; 2019 Dec; 137(12):1381-1388. PubMed ID: 31580392
[TBL] [Abstract][Full Text] [Related]
8. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J
Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654
[TBL] [Abstract][Full Text] [Related]
9. Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.
Sengillo JD; Gregori NZ; Sisk RA; Weng CY; Berrocal AM; Davis JL; Mendoza-Santiesteban CE; Zheng DD; Feuer WJ; Lam BL
Ophthalmol Retina; 2022 Apr; 6(4):273-283. PubMed ID: 34896323
[TBL] [Abstract][Full Text] [Related]
10. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial.
Koenekoop RK; Sui R; Sallum J; van den Born LI; Ajlan R; Khan A; den Hollander AI; Cremers FP; Mendola JD; Bittner AK; Dagnelie G; Schuchard RA; Saperstein DA
Lancet; 2014 Oct; 384(9953):1513-20. PubMed ID: 25030840
[TBL] [Abstract][Full Text] [Related]
11. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].
Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI
Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591
[TBL] [Abstract][Full Text] [Related]
12. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2.
Testa F; Maguire AM; Rossi S; Pierce EA; Melillo P; Marshall K; Banfi S; Surace EM; Sun J; Acerra C; Wright JF; Wellman J; High KA; Auricchio A; Bennett J; Simonelli F
Ophthalmology; 2013 Jun; 120(6):1283-91. PubMed ID: 23474247
[TBL] [Abstract][Full Text] [Related]
13. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.
Hussain RM; Tran KD; Maguire AM; Berrocal AM
Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202
[TBL] [Abstract][Full Text] [Related]
14. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
[TBL] [Abstract][Full Text] [Related]
15. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C; Scott LJ
Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
[TBL] [Abstract][Full Text] [Related]
17. Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.
Kolesnikova M; Lima de Carvalho JR; Parmann R; Kim AH; Mahajan VB; Tsang SH; Sparrow JR
Mol Genet Genomic Med; 2022 Nov; 10(11):e2038. PubMed ID: 36225124
[TBL] [Abstract][Full Text] [Related]
18. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
[TBL] [Abstract][Full Text] [Related]
19. Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa.
Kwak JJ; Kim HR; Byeon SH
Yonsei Med J; 2022 Jul; 63(7):701-705. PubMed ID: 35748082
[TBL] [Abstract][Full Text] [Related]
20. Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations.
Roman AJ; Cideciyan AV; Schwartz SB; Olivares MB; Heon E; Jacobson SG
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1378-83. PubMed ID: 23341016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
